Meditera Tibbi Malzeme Sanayi ve Ticaret Anonim Sirketi

IBSE:MEDTR Stock Report

Market Cap: ₺5.4b

Meditera Tibbi Malzeme Sanayi ve Ticaret Anonim Sirketi Past Earnings Performance

Past criteria checks 2/6

Meditera Tibbi Malzeme Sanayi ve Ticaret Anonim Sirketi's earnings have been declining at an average annual rate of -22.4%, while the Medical Equipment industry saw earnings growing at 8% annually. Revenues have been growing at an average rate of 38.5% per year. Meditera Tibbi Malzeme Sanayi ve Ticaret Anonim Sirketi's return on equity is 6.2%, and it has net margins of 9.1%.

Key information

-22.4%

Earnings growth rate

-29.5%

EPS growth rate

Medical Equipment Industry Growth12.3%
Revenue growth rate38.5%
Return on equity6.2%
Net Margin9.1%
Last Earnings Update30 Sep 2024

Recent past performance updates

Recent updates

Revenue & Expenses Breakdown

How Meditera Tibbi Malzeme Sanayi ve Ticaret Anonim Sirketi makes and spends money. Based on latest reported earnings, on an LTM basis.


Earnings and Revenue History

IBSE:MEDTR Revenue, expenses and earnings (TRY Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
30 Sep 241,40712931815
30 Jun 241,393-1630714
31 Mar 241,5049329514
31 Dec 231,4522628814
30 Sep 232,511-16645216
30 Jun 232,1913438214
31 Mar 231,848-1131111
31 Dec 221,5961142427
30 Sep 227313591075
30 Jun 22607304913
31 Mar 22471226763
31 Dec 21376168672
30 Sep 2136459660
30 Jun 2137068671
31 Mar 2136262660
31 Dec 2035960641

Quality Earnings: MEDTR has high quality earnings.

Growing Profit Margin: MEDTR became profitable in the past.


Free Cash Flow vs Earnings Analysis


Past Earnings Growth Analysis

Earnings Trend: MEDTR's earnings have declined by 22.4% per year over the past 5 years.

Accelerating Growth: MEDTR has become profitable in the last year, making the earnings growth rate difficult to compare to its 5-year average.

Earnings vs Industry: MEDTR has become profitable in the last year, making it difficult to compare its past year earnings growth to the Medical Equipment industry (-2%).


Return on Equity

High ROE: MEDTR's Return on Equity (6.2%) is considered low.


Return on Assets


Return on Capital Employed


Discover strong past performing companies

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/02/05 17:36
End of Day Share Price 2025/02/05 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Meditera Tibbi Malzeme Sanayi ve Ticaret Anonim Sirketi is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.